Optimize your syngeneic models with genetically engineered cell lines

While syngeneic models represent a very powerful tool to assess tumor immune response in immunotherapy, there are a few concerns about the translational value derived from studies using such models.

In this webinar, Dr Amélie Rezza explains how well-designed and thoroughly characterized genetically modified tumor cell lines can optimize syngeneic models by maximizing their clinical relevance.

  • Challenges of gene editing in tumor cell lines used in syngeneic models
  • genOway’s optimized platform for cell line gene engineering
  • Brief introduction to the validated MC38-hPDL1 cell model


Duration: 20-minute presentation + 10-minute Q&A